Sanne de Bruin1, Lieuwe D Bos1, Marian A van Roon2, Anita M Tuip-de Boer1, Alex R Schuurman3, Marleen J A Koel-Simmelinck4, Harm Jan Bogaard5, Pieter Roel Tuinman6, Michiel A van Agtmael7, Jörg Hamann8, Charlotte E Teunissen4, W Joost Wiersinga3, A H Koos Zwinderman9, Matthijs C Brouwer2, Diederik van de Beek10, Alexander P J Vlaar1. 1. From the Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 2. Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands. 3. Department of Infectious Diseases, University of Amsterdam, Amsterdam UMC, Amsterdam Infection and Immunity, Amsterdam, The Netherlands. 4. Neurochemistry Laboratory, Department of Clinical Chemistry, Free University, Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, the Netherlands. 5. Department of Pulmonary Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. 6. Department of Intensive Care, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 7. Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 8. Biobank Core Facility, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. 9. Department of Clinical Epidemiology and Biostatistics, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Amsterdam, the Netherlands. 10. Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands. Electronic address: d.vandebeek@amsterdamumc.nl.
Abstract
BACKGROUND: Mortality rates are high among hospitalized patients with COVID-19, especially in those intubated on the ICU. Insight in pathways associated with unfavourable outcome may lead to new treatment strategies. METHODS: We performed a prospective cohort study of patients with COVID-19 admitted to general ward or ICU who underwent serial blood sampling. To provide insight in the pathways involved in disease progression, associations were estimated between outcome risk and serial measurements of 64 biomarkers in potential important pathways of COVID-19 infection (inflammation, tissue damage, complement system, coagulation and fibrinolysis) using joint models combining Cox regression and linear mixed-effects models. For patients admitted to the general ward, the primary outcome was admission to the ICU or mortality (unfavourable outcome). For patients admitted to the ICU, the primary outcome was 12-week mortality. FINDINGS: A total of 219 patients were included: 136 (62%) on the ward and 119 patients (54%) on the ICU; 36 patients (26%) were included in both cohorts because they were transferred from general ward to ICU. On the general ward, 54 of 136 patients (40%) had an unfavourable outcome and 31 (23%) patients died. On the ICU, 54 out of 119 patients (45%) died. Unfavourable outcome on the general ward was associated with changes in concentrations of IL-6, IL-8, IL-10, soluble Receptor for Advanced Glycation End Products (sRAGE), vascular cell adhesion molecule 1 (VCAM-1) and Pentraxin-3. Death on the ICU was associated with changes in IL-6, IL-8, IL-10, sRAGE, VCAM-1, Pentraxin-3, urokinase-type plasminogen activator receptor, IL-1-receptor antagonist, CD14, procalcitonin, tumor necrosis factor alfa, tissue factor, complement component 5a, Growth arrest-specific 6, angiopoietin 2, and lactoferrin. Pathway analysis showed that unfavourable outcome on the ward was mainly driven by chemotaxis and interleukin production, whereas death on ICU was associated with a variety of pathways including chemotaxis, cell-cell adhesion, innate host response mechanisms, including the complement system, viral life cycle regulation, angiogenesis, wound healing and response to corticosteroids. INTERPRETATION: Clinical deterioration in patients with severe COVID-19 involves multiple pathways, including chemotaxis and interleukin production, but also endothelial dysfunction, the complement system, and immunothrombosis. Prognostic markers showed considerable overlap between general ward and ICU patients, but we identified distinct differences between groups that should be considered in the development and timing of interventional therapies in COVID-19. FUNDING: Amsterdam UMC, Amsterdam UMC Corona Fund, and Dr. C.J. Vaillant Fonds.
BACKGROUND:Mortality rates are high among hospitalized patients with COVID-19, especially in those intubated on the ICU. Insight in pathways associated with unfavourable outcome may lead to new treatment strategies. METHODS: We performed a prospective cohort study of patients with COVID-19 admitted to general ward or ICU who underwent serial blood sampling. To provide insight in the pathways involved in disease progression, associations were estimated between outcome risk and serial measurements of 64 biomarkers in potential important pathways of COVID-19infection (inflammation, tissue damage, complement system, coagulation and fibrinolysis) using joint models combining Cox regression and linear mixed-effects models. For patients admitted to the general ward, the primary outcome was admission to the ICU or mortality (unfavourable outcome). For patients admitted to the ICU, the primary outcome was 12-week mortality. FINDINGS: A total of 219 patients were included: 136 (62%) on the ward and 119 patients (54%) on the ICU; 36 patients (26%) were included in both cohorts because they were transferred from general ward to ICU. On the general ward, 54 of 136 patients (40%) had an unfavourable outcome and 31 (23%) patientsdied. On the ICU, 54 out of 119 patients (45%) died. Unfavourable outcome on the general ward was associated with changes in concentrations of IL-6, IL-8, IL-10, soluble Receptor for Advanced Glycation End Products (sRAGE), vascular cell adhesion molecule 1 (VCAM-1) and Pentraxin-3. Death on the ICU was associated with changes in IL-6, IL-8, IL-10, sRAGE, VCAM-1, Pentraxin-3, urokinase-type plasminogen activator receptor, IL-1-receptor antagonist, CD14, procalcitonin, tumor necrosis factor alfa, tissue factor, complement component 5a, Growth arrest-specific 6, angiopoietin 2, and lactoferrin. Pathway analysis showed that unfavourable outcome on the ward was mainly driven by chemotaxis and interleukin production, whereas death on ICU was associated with a variety of pathways including chemotaxis, cell-cell adhesion, innate host response mechanisms, including the complement system, viral life cycle regulation, angiogenesis, wound healing and response to corticosteroids. INTERPRETATION: Clinical deterioration in patients with severe COVID-19 involves multiple pathways, including chemotaxis and interleukin production, but also endothelial dysfunction, the complement system, and immunothrombosis. Prognostic markers showed considerable overlap between general ward and ICU patients, but we identified distinct differences between groups that should be considered in the development and timing of interventional therapies in COVID-19. FUNDING: Amsterdam UMC, Amsterdam UMC Corona Fund, and Dr. C.J. Vaillant Fonds.
Authors: Isabel Cornejo-Pareja; Isabel M Vegas-Aguilar; Henry Lukaski; Antonio Talluri; Diego Bellido-Guerrero; Francisco J Tinahones; Jose Manuel García-Almeida Journal: Nutrients Date: 2022-06-30 Impact factor: 6.706
Authors: Frank L van de Veerdonk; Evangelos Giamarellos-Bourboulis; Peter Pickkers; Lennie Derde; Helen Leavis; Reinout van Crevel; Job J Engel; W Joost Wiersinga; Alexander P J Vlaar; Manu Shankar-Hari; Tom van der Poll; Marc Bonten; Derek C Angus; Jos W M van der Meer; Mihai G Netea Journal: Nat Med Date: 2022-01-21 Impact factor: 87.241
Authors: Diana A Gorog; Robert F Storey; Paul A Gurbel; Udaya S Tantry; Jeffrey S Berger; Mark Y Chan; Daniel Duerschmied; Susan S Smyth; William A E Parker; Ramzi A Ajjan; Gemma Vilahur; Lina Badimon; Jurrien M Ten Berg; Hugo Ten Cate; Flora Peyvandi; Taia T Wang; Richard C Becker Journal: Nat Rev Cardiol Date: 2022-01-13 Impact factor: 49.421
Authors: Marleen A Slim; Brent Appelman; Marcella C A Müller; Matthijs C Brouwer; Alexander P J Vlaar; W Joost Wiersinga; Lonneke A van Vught Journal: Eur J Clin Microbiol Infect Dis Date: 2021-10-28 Impact factor: 3.267
Authors: Katherine D Wick; Lianne Siegel; James D Neaton; Cathryn Oldmixon; Jens Lundgren; Robin L Dewar; H Clifford Lane; B Taylor Thompson; Michael A Matthay Journal: JCI Insight Date: 2022-05-09
Authors: Christoph C Kaufmann; Amro Ahmed; Achim Leo Burger; Marie Muthspiel; Bernhard Jäger; Johann Wojta; Kurt Huber Journal: Cells Date: 2022-03-08 Impact factor: 6.600